EUTCD-grade stem cell lines
EUTCD-grade stem cell lines are suitable for the development of cell therapies and meet the requirements of the European Tissue and Cells Directive (EUTCD) for the quality and safety assurance of patient treatments. All EUTCD-grade cell lines undergo a process known as Due Diligence, to ensure compliancy with the EU Tissue and Cells Directives (under HTA direction) prior to deposition, and their subsequent banking and distribution for human application. The EUTCD-grade cell lines have been derived from embryos under informed consent requirements of the UK Human Fertilisation and Embryology Authority (HFEA) and have been reviewed by the independent UK Stem Cell Bank Steering Committee (UK Steering Committee).
To obtain human embryonic stem cell lines from the UK Stem Cell Bank, an application to UK Steering Committee must first be submitted and approved. Please follow the guidelines on our page Apply for Stem Cell Lines.
EUCTD-grade cell lines catalogue
The UK Stem Cell Bank has an ongoing banking program that aims to provide over 20 feeder-free EUTCD-grade hESC banks with matched-research banks by 2020.
Below is the Quality Control (QC) information generated by the UK Stem Cell Bank for cell lines available for distribution (bold) or under final review. A Certificate of Analysis is provided with each order. For further details on upcoming cell lines, or those under banking or QC stages please contact enquiries@ukstemcellbank.org.uk.
KCL lines are deposited by King’s College London. MasterShef lines are deposited by University of Sheffield, Centre for Stem Cell Biology. MAN lines are deposited by University of Manchester. RC lines are deposited by Roslin Cells.
Feeder free EUTCD-grade cell lines
The UK Stem Cell Bank provides EUTCD-grade hESC lines adapted for growth and retention of the undifferentiated state in a xeno-free culture system, without the need for feeder cells.
| | Standard characterisation
|
| |
|
|---|
| Cell line | UK steering committee number | Microbiological safety testing | Viability and morphology | Undifferentiated cell analysis | Differentiation potency | STR/HLA profile** | Karyotype | Cancer panel |
Release status
|
Matched research bank
|
|---|
| KCL-031 |
SCSC12-37 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46 XY |
✔
|
Pre-release
|
✔
|
| KCL-032 |
SCSC12-37 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XX |
✔
|
Pre-release
|
✔
|
| KCL-033 |
SCSC11-54 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XX |
|
Pre-release
|
✔
|
| KCL-034 |
SCSC11-54 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
✔
|
Pre-release |
✔
|
| MAN-11 |
SCSC12-26 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XX |
✔
|
Final review
|
|
| MAN-12 |
SCSC12-27 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
✔
|
Final review |
|
| MAN-13 |
SCSC12-28
|
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
|
Final review
|
|
| MAN-14 |
SCSC12-23 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XX |
✔
|
Final review
|
|
| MAN-15 |
SCSC12-24 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
✔
|
Final review
|
|
| MAN-16 |
SCSC12-25 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
✔
|
Pre-release
|
✔
|
| MasterShef4 |
SCSC12-05 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
✔
|
Pre-release
|
✔
|
| MasterShef5 |
SCSC12-06 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XX |
✔
|
Final review
|
|
| MasterShef7 |
SCSC12-08 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
✔
|
Final review
|
|
| RC11 |
SCSC11-02 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XX |
✔
|
Pre-release
|
✔
|
| RC17 |
SCSC12-37 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XX |
|
Pre-release
|
✔
|
Feeder dependent EUTCD-grade cell lines
The UK Stem Cell Bank also provides EUTCD-grade hESC lines for classical, feeder-dependent culture systems. Our cell banks are grown and maintained on quality-controlled primary MEFs, virus and sterility tested, and qualified for viability and stem cell supportiveness.
| | Standard characterisation
|
| |
|
|---|
| Cell line | UK steering committee number | Microbiological safety testing | Viability and morphology | Undifferentiated cell analysis | Differentiation potency | STR/HLA profile** | Karyotype | Cancer panel |
Release status
|
Matched research bank
|
|---|
| KCL-033 |
SCSC12-54 |
✔*
|
✔
|
✔
|
✔
|
✔
|
n/a |
|
Special release
|
|
| MAN-11 |
SCSC12-26 |
✔
|
✔
|
✔
|
✔
|
✔
|
46XX |
|
Final review
|
|
| MAN-12 |
SCSC12-27 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
|
Final review |
|
| MAN-13 |
SCSC12-28
|
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
|
Final review
|
|
| MAN-14 |
SCSC12-23 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XX |
|
Final review
|
|
| MAN-15 |
SCSC12-24 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
|
Final review
|
|
| MAN-16 |
SCSC12-25 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
|
Final review
|
|
| MasterShef2 |
SCSC12-03 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XX |
|
Released |
✔
|
| MasterShef4 |
SCSC12-05 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
|
Final review
|
|
| MasterShef7 |
SCSC12-08 |
✔*
|
✔
|
✔
|
✔
|
✔
|
46XY |
|
Released
|
✔
|
| MasterShef10 |
SCSC11-02 |
✔
|
✔
|
✔
|
✔
|
✔
|
46XY |
|
Released
|
✔
|
* Awaiting final review of ongoing viral testing
** Human Leukocyte Antigen (HLA) data provided by the Depositor Centre.
*** Please Note - EUTCD-Grade cell line MasterShef 10 was produced aseptically in accordance with The Human Tissue (Quality and Safety for Human Application) Regulations 2007 under a licence granted by the Human Tissue Authority. Digital PCR and whole exome sequencing of deposited material identified two TP53 mutations (R248W and G245S). For more information refer to Merkle et al., Human Pluripotent Cells Recurrently Acquire and Expand Dominant Negative P53 Mutations, Nature (2017) doi: 10.1038/nature22312.
In the event of a Serious Adverse Event or Reaction (SAEAR) when using the EUTCD grade cell lines, please contact both HTA and UK Stem Cell Bank within 24 hours. For any uncertainty
or clarification on SAEAR please contact us at enquiries@ukstemcellbank.org.uk. For more information about SAEAR please follow HTA instructions.